Compare ResMed Inc. (RMD) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Global X SuperDividend ETF — how do they compare? ResMed Inc. trades at $225.92 (market cap $31.78B), while Global X SuperDividend ETF trades at $23.75 (market cap $1.17B). The key difference: ResMed Inc. is far larger — about 27.2× Global X SuperDividend ETF's market cap, and ResMed Inc. pays a 1.17% dividend while Global X SuperDividend ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Global X SuperDividend ETF for 47 Days on average.
| RMD | SDIV | |
|---|---|---|
Market Cap | $31.78B | $1.17B |
Volume | 1,128,382 | 432,039 |
Sector | Health | Broad Market / Factor |
52-Week High | $277.88 | $26.34 |
52-Week Low | $182.82 | $22.90 |
Typical Hold Time | 51 Days | 47 Days |
Enterprise Value | $31.14B | — |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
SDIV trades at $23.58, down 0.55% with a bearish technical signal from moving averages. The ETF maintains an 8%+ dividend yield but faces scrutiny over principal erosion, having lost 66% since inception. Recent institutional buying by Ameritas Advisory contrasts with negative media coverage questioning sustainability of high yields amid capital depreciation.
Outlook remains challenged by structural underperformance versus benchmarks. The high yield attracts income seekers but masks negative growth and volatility risks. Investment case hinges on yield sustainability versus capital preservation, with analyst sentiment cautious given persistent track record of value destruction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
